89bio, Inc. (ETNB)
NASDAQ: ETNB · IEX Real-Time Price · USD
8.07
-0.28 (-3.35%)
Jul 22, 2024, 10:34 AM EDT - Market open
89bio Employees
89bio had 70 employees as of December 31, 2023. The number of employees increased by 25 or 55.56% compared to the previous year.
Employees
70
Change (1Y)
25
Growth (1Y)
55.56%
Revenue / Employee
n/a
Profits / Employee
-$2,357,629
Market Cap
799.86M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 70 | 25 | 55.56% |
Dec 31, 2022 | 45 | 4 | 9.76% |
Dec 31, 2021 | 41 | 14 | 51.85% |
Dec 31, 2020 | 27 | 7 | 35.00% |
Dec 31, 2019 | 20 | - | - |
Related Stocks
Company Name | Employees |
---|---|
The Pennant Group | 5,791 |
InnovAge Holding | 2,100 |
CureVac | 1,172 |
GeneDx Holdings | 1,000 |
Atrion | 712 |
Cytek Biosciences | 676 |
Clover Health Investments | 552 |
Standard BioTools | 539 |
ETNB News
- 9 days ago - 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - 89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress - GlobeNewsWire
- 2 months ago - 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis - GlobeNewsWire
- 2 months ago - 89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - 89bio to Participate in the BofA Securities 2024 Health Care Conference - GlobeNewsWire
- 2 months ago - 89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH - GlobeNewsWire
- 3 months ago - 89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors - GlobeNewsWire
- 4 months ago - 89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis - GlobeNewsWire